April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Developing a Pressure-inducible Gene Therapy Vector for the Treatment of Elevated Intraocular Pressure (IOP)
Author Affiliations & Notes
  • Juan Carabana
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
  • N. Comes
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
  • T. Borras
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
  • Footnotes
    Commercial Relationships  Juan Carabana, None; N. Comes, None; T. Borras, None
  • Footnotes
    Support  NIH Grant EY11906, EY13126, RPB
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4623. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Juan Carabana, N. Comes, T. Borras; Developing a Pressure-inducible Gene Therapy Vector for the Treatment of Elevated Intraocular Pressure (IOP). Invest. Ophthalmol. Vis. Sci. 2011;52(14):4623.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Our long-term goal is to develop inducible gene therapy vectors which will express a transgene under glaucomatous conditions. Our purpose here was to identify promoter sequences which would respond to elevated IOP and drive up the expression of a reporter gene. We selected the Matrix Gla (MGP) gene, whose expression we have shown to be highly upregulated by elevated IOP (HP) in the human trabecular meshwork (TM) tissue (1).

Methods: : The MGP DNA promoter sequences (-748/+30) were amplified from pooled human genomic DNA (gDNA), sequence-verified and inserted into a promoterless secreted alkaline phosphatase (SEAP) reporter vector. The expression cassette (MGPpromoter-SEAP) was cloned into a pShuttle vector to generate a replication deficient Adenovirus (AdhMGP.SEAP). Human perfused anterior segments (n=2 pairs at submission) were perfused at 3-4 µl/min for 24h and then valve-injected with 20µl of the AdhMGP.SEAP high-titer stock. After infection, the flow of one eye was raised to achieve a ΔP of 30 mmHg, while the contralateral eye was left at baseline pressure (CP). Eyes were further perfused at their new constant P for 4 days (OD ΔP=30; OS ΔP=0). Effluents were collected every day for analysis of SEAP (chemiluminescence assay). At the end of the experiment, TM tissues were dissected and halved for RNA or DNA extraction to quantify SEAP transcripts and viral genomes by TaqMan PCR. Amplification values were normalized by 18S.cDNA and 18S.gDNA respectively. SEAP levels were normalized by the number of viral genomes in each TM.

Results: : SEAP was detected in all effluents at 48h and increased thereafter at each time point (2-20µg/ml), indicating that MGP sequences -748/+30 contain a strong promoter for expression in the human TM tissue. After correction for the number of viral genomes in each TM, the SEAP levels in the effluents from the eyes subjected to HP were 27.8X (pair #1) and 3.3X (pair #2) higher than in the CP control eye. Similarly, the SEAP transcripts present in the TM tissue at the end of experiment were 1.6X higher in the HP eye than in the CP control eye (both pairs).

Conclusions: : In addition to containing promoter signaling sequences, the MGP -748/30 upstream-region seems to include regulatory elements that increase expression of the driven gene in the presence of HP. These pressure-responding regulatory elements function in the intact human perfused TM. Fusion of these sequences to candidate genes would allow controlled expression of therapeutic genes during a HP episode. This advance could help manage a future treatment of glaucoma by gene therapy.(1) Comes and Borras. Physiol Genomics 38,205(2009)

Keywords: trabecular meshwork • gene transfer/gene therapy • gene/expression 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×